MDM2 and neoplasm: NRF2 activation plays a critical role in the treatment resistance of FH mutation-induced type-2 pRCC (FHpRCC) tumor cells in addition to the high expression of XIAP, MDM2, p-Akt, etc. Metastatic pRCC continues to have limited treatment options [104].